Fig. 3: HPA-12 in combination with Creno eradicates AML in a xenograft model.

a Schematic diagram of the experimental design. The mice were randomly allocated into four groups and treated with Creno (15 mg/kg), HPA-12 (4 mg/kg), or Combo (n = 8 mice per group). b In vivo bioluminescence imaging of B-NDG mice on Day 7 and Day 27 (n = 5 per group). Five mice from each group were randomly chosen for bioluminescence imaging and survival analysis on Day 27. c Overall survival of the mice in each treatment group (n = 5 per group). The P values were calculated with a log-rank (Mantel‒Cox) test. Images of the spleen size (d) and weight (e) were acquired once the mice were euthanized on Day 27 (n = 3 per group). f, g Representative images of leukemia infiltration in the BM and spleen as analyzed by immunohistochemistry (IHC) staining of human CD45 (hCD45). Scale bar, 50 µm. Slides from one mouse per group were randomly chosen for IHC staining. BM, bone marrow. h Body weights of treated mice. Body weights were measured every two days and are presented as the means for each group (n = 8 mice). i Statistical analysis of the percentage of human CD33⁺/human CD45⁺ (hCD33⁺/hCD45⁺) cells in the BM (n = 3 mice). i Statistical analysis of the percentage of human CD33⁺/human CD45⁺ (hCD33⁺/hCD45⁺) cells in the BM. Representative flow plots are shown in Fig. S4a. Three mice in each group were sacrificed on Day 27 for leukemic burden analysis. The data are presented as the means ± SDs, and differences were compared by 2-tailed Student’s t tests. Multiple groups were analyzed with one-way ANOVA. ns: not significant, *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Source data are provided as a source data file.